Pacific Fertility Center is pleased to be involved in a six month study that will provide research data comparing two different methods of delivering enhanced progesterone to women after in vitro fertilization. Progesterone is a hormone that is produced by the ovaries after ovulation. Progesterone support is important for initiating implantation and supporting the embryo through the first months of growth.

Some women benefit from direct delivery of progesterone to enhance the implantation process.

The current protocol for direct progesterone application is via vaginal suppositories. Endometrin is an effervescent tablet that is inserted vaginally and absorbed locally to provide progesterone to the developing uterine lining and to provide support of pregnancy. The study aims to demonstrate the equivalence in maintaining pregnancy of the new medication to an existing FDA approved medication.

PFC is currently recruiting up to 25 women experiencing infertility to take part in this clinical research study.

The participants must be non-smokers between the ages of 18 and 42, with two functioning ovaries and a Body Mass Index of 34 or below. Additional screening will be conducted to determine if a patient is eligible to participate. Women who qualify and undergo an IVF treatment cycle will receive free medications and a reduction in IVF fees. Individuals interested in participating are invited to contact Dr. Philip Chenette at (415) 834-3000, or (888)-834-3095.

– Philip Chenette, MD

Tags: Clinical Trials & Studies, IVF - In Vitro Fertilization, Medications

This entry was posted on Friday, September 23rd, 2005 at 8:45 pm and is filed under From Us To You. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.